Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

点击蓝字关注我们【导读】癌症疫苗面临的一个基本挑战，是如何产生对肿瘤抗原具有特异性的长效功能性T细胞。在这项研究中，团队发现针对体细胞突变衍生的新抗原的mRNA脂质体疫苗，可以解决胰腺导管腺癌（PDAC）的这一难题。2025年2月19日，美国纪念斯隆 ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...

Credit: Memorial Sloan Kettering Cancer Center Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has ...

"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...